A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. Howeve... Ausführliche Beschreibung

1. Person: Ma Li verfasserin
Weitere Personen: Men Yu verfasserin; Feng Lingling verfasserin; Kang Jingjing verfasserin; Sun Xin verfasserin; Yuan Meng verfasserin; Jiang Wei verfasserin; Hui Zhouguang verfasserin
Quelle: In Radiology and Oncology (01.03.2019)
Weitere Artikel
Format: Online-Artikel
Sprache: English
Veröffentlicht: 2019
Beschreibung: Online-Ressource
Online Zugang: Online
Online
Online
Online
Volltext
Tags: Hinzufügen
Keine Tags. Fügen Sie den ersten Tag hinzu!
  Creative Commons License Source: Directory of Open Access Journals (DOAJ).
Zusammenfassung: The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.
ISSN: 1581-3207

Ähnliche Einträge

Keine ähnlichen Titel gefunden

Privacy Notice Ask a Librarian New Acquisitions